Many of the 20,000-odd Australian men receiving treatment for prostate cancer are set to benefit from a new six-monthly injection that delays the cancer's progress.

The injection, known as Eligard, suppresses testosterone production which stops the growth of cancer cells and reduces the number of injections sufferers need to just two a year.

It can keep cancer in remission and is available on the Pharmaceutical Benefits Scheme.

Even then he won't have to go in to hospital, just a doctor's visit for a six-monthly injection, for his Eligard treatment, to keeps his cancer in check.

"I'm overjoyed, because in terms of quality of life, it's certainly a benefit to the patient," Mr Oliver said.

The male hormone testosterone that makes prostate cancer grow can be operated on or reduced with radiation if caught early.

But if it has spread, hormone injections help delay cancer's progression; this latest formulation is injected as a gel — active ingredients released slowly over the next six months.

"By giving hormone therapy we're blocking testosterone and in 90 percent of men we're sending the prostate cancer into remission," said Dr Phillip Katelaris, a urological surgeon with the Prostate Cancer Rehabilitation Centre in Sydney.